Abstract
Five children with human immunodeficiency virus type-1 (HIV-1) infection, aged 4 to 13 years, manifested extrapyramidal dysfunction characterized by rigidity/stiffness, ambulation difficulties/shuffling gait, dysarthria/drooling/swallowing dysfunction, hypomimetic/inexpressive facies, and bradykinesia. Levodopa therapy caused an initial improvement in all symptoms, and the effect was sustained in most patients. Levodopa is a useful adjunctive therapy in HIV-1-infected children with extrapyramidal syndromes, by enhancing motor function and improving their quality of life.
Citations
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J W LanceM Vidailhet
Feb 14, 2003·Current Neurology and Neuroscience Reports·Lucy Civitello
Dec 31, 2003·Neurotoxicology·E KoutsilieriP Riederer
Jun 5, 2004·Parkinsonism & Related Disorders·B C L LaiJ K C Tsui
Sep 15, 2010·Journal of Tropical Pediatrics·Regan SolomonsRonald van Toorn
Oct 6, 2000·Clinical Neuropharmacology·A di RoccoD Simpson
Mar 4, 2009·Expert Review of Anti-infective Therapy·Katy M WebbRosemarie M Booze
Aug 5, 2008·Brain Research·Sylvia FittingCharles F Mactutus
Jul 21, 2004·Parkinsonism & Related Disorders·Winona TseWilliam Koller
Aug 20, 2016·Journal of Neurovirology·Kristen A McLaurinCharles F Mactutus
Sep 7, 2016·Scientific Reports·Kristen A McLaurinCharles F Mactutus
Dec 6, 2000·Journal of Psychopharmacology·A NathM Mattson
Nov 8, 2017·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Sylvia FittingCharles F Mactutus
Sep 25, 2002·CNS Drugs·Francisco Cardoso
Jan 8, 2021·Curēus·Mohammad AlmajaliPratap Chand
Jul 3, 2021·Journal of Clinical Medicine·Giacomo GaroneAlessandro Capuano